<SEC-DOCUMENT>0001493152-23-018718.txt : 20230523
<SEC-HEADER>0001493152-23-018718.hdr.sgml : 20230523
<ACCEPTANCE-DATETIME>20230523160524
ACCESSION NUMBER:		0001493152-23-018718
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230522
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230523
DATE AS OF CHANGE:		20230523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		23948943

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:MBOT="http://microbotmedical.com/20230522">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_MBOT_microbotmedical.com_20230522 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20230522_20230522 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000883975 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityCentralIndexKey">0000883975</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mbot-20230522.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-05-22to2023-05-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-22</xbrli:startDate>
        <xbrli:endDate>2023-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20230522__20230522_ztY9pyyMc3uk"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_904_edei--DocumentPeriodEndDate_c20230522__20230522_zVmxjiUcnsGe"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 22, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20230522__20230522_zgMawAlNlF03"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityRegistrantName">MICROBOT
MEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230522__20230522_zaKCtwbSuZ1"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20230522__20230522_zrG58tSpm84a"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityFileNumber">000-19871</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230522__20230522_zaDJ8f2ZSov9"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityTaxIdentificationNumber">94-3078125</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission </b></span></p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230522__20230522_zWzECM9yu46i"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityAddressAddressLine1">25
Recreation Park Drive</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20230522__20230522_zzt6j6fHGGQ3"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityAddressAddressLine2">Unit 108</ix:nonNumeric></span></b><br/>
<b><span id="xdx_900_edei--EntityAddressCityOrTown_c20230522__20230522_zEXfUGhqYrm6"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityAddressCityOrTown">Hingham</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230522__20230522_zrg5z5FnEoX8"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20230522__20230522_zgv01f2R1Ola"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:EntityAddressPostalZipCode">02043</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_903_edei--CityAreaCode_c20230522__20230522_zt7V1MJrwiy7"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:CityAreaCode">(781)</ix:nonNumeric></span> <span id="xdx_901_edei--LocalPhoneNumber_c20230522__20230522_zppxiyB5Blz5"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:LocalPhoneNumber">875-3605</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20230522__20230522_zdIWaQRD7dn7"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; width: 0.25in"><span id="xdx_907_edei--SolicitingMaterial_c20230522__20230522_znU5If3zOUM"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20230522__20230522_z9p02QQ6vVDg"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.25in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20230522__20230522_zGDue40uRG7"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20230522__20230522_zUTRFSEgzKJ3"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20230522__20230522_zNLXLolwqTJk"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" name="dei:TradingSymbol">MBOT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_909_edei--SecurityExchangeName_c20230522__20230522_zZidYnFAZ9pb"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20230522__20230522_z23VnzbJC2Qh"><ix:nonNumeric contextRef="From2023-05-22to2023-05-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2023, Microbot Medical Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement
(the &#8220;Purchase Agreement&#8221;) with an institutional investor (the &#8220;Investor&#8221;), pursuant to which the Company agreed
to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the &#8220;Offering&#8221;),
an aggregate of 655,569 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (&#8220;Common
Stock&#8221;), at an offering price of $2.20 per share, for aggregate gross proceeds from the Offering of approximately $1.4 million
before deducting the placement agent fee (as described in greater detail below) and related offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification
rights and obligations of the parties. Pursuant to the terms of the Purchase Agreement, the Company has agreed to certain restrictions
on the issuance and sale of its Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) during the 5-trading
day period following the closing of the Offering.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-250966), which was filed with the Securities
and Exchange Commission (the &#8220;Commission&#8221;) on November 25, 2020 and was declared effective by the Commission on December
4, 2020 (the &#8220;Registration Statement&#8221;), a base prospectus dated December 4, 2020 and a prospectus supplement dated May 22,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the &#8220;Engagement Letter&#8221;)
with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;), pursuant to which Wainwright agreed to serve as the exclusive placement
agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement. As compensation for such placement agent
services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company
from the Offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Offering, a non-accountable
expense of $25,000, up to $35,000 for its fees and expenses of legal counsel</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$15,950 for clearing expenses. The Company has also agreed to issue to Wainwright or its designees preferred
investment options</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to purchase 32,778 shares of
Common Stock (the &#8220;Wainwright Warrants&#8221;). The Wainwright Warrants will be exercisable six months following issuance, have
a term of three and a half years from the commencement of sales in the Offering, and have an exercise price of $2.75 per share. Further,
pursuant to the Engagement Letter, Wainwright is entitled to compensation with respect to any financing of the Company occurring within
six months of the termination of the Engagement Letter when such financing is provided by investors whom Wainwright introduced to the
Company during the term of the Engagement Letter. Further, pursuant to the Engagement Letter, Wainwright has a right of first refusal
to act as sole book-running manager, sole underwriter or sole placement agent with respect to any public offering or private placement
of equity, equity-linked or debt securities using an underwriter or placement agent occurring during the twelve-month period following
the termination of the Engagement Letter. The Engagement Letter also includes indemnification obligations of the Company and other provisions
customary for transactions of this nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
of the Wainwright Warrants nor the shares of Common Stock issuable upon the exercise of the Wainwright Warrants (the &#8220;Warrant Shares&#8221;)
are registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Wainwright Warrants and the Warrant
Shares were issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock is listed on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
foregoing summaries of the form of Wainwright Warrant and the Purchase Agreement do not purport to be complete and are subject to, and
qualified in their entirety by, such documents attached as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K, which
are incorporated herein by reference.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor
shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. relating to the legality of the issuance and sale of the Shares
is attached as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02. Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 above related to the Wainwright Warrants and the Warrant Shares is incorporated herein by reference
into this Item 3.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01. Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2023, the Company issued a press release announcing the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated
by reference into this Item 8.01 of this Current Report on Form 8-K. On May 23, 2023, the Company issued a press release announcing the
closing of the Offering, a copy of which is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01 of this
Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 0.75in"><p style="text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
                                                                                <p style="text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Wainwright Warrant.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated as of May 22, 2023, by and among the Company and the purchasers party thereto.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Pricing Press Release.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><a href="ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Press Release.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MICROBOT
    MEDICAL INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Harel Gadot</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 23, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Investment Option
Shares: ______ </FONT></TD><TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: November 23, 2023</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received,
_____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m. (New York City time) on November 23, 2026 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares
(as subject to adjustment hereunder, the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).
This Preferred Investment Option is being issued pursuant to that certain Engagement Agreement between the Company and H.C. Wainwright
&amp; Co., LLC, dated as of May 16, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated May 22, 2023, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Preferred Investment Option to the Company until the Holder has purchased all of the
Preferred Investment Option Shares available hereunder and the Preferred Investment Option has been exercised in full, in which case,
the Holder shall surrender this Preferred Investment Option to the Company for cancellation as soon as reasonably practicable of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Preferred Investment Option resulting
in purchases of a portion of the total number of Preferred Investment Option Shares available hereunder shall have the effect of lowering
the outstanding number of Preferred Investment Option Shares purchasable hereunder in an amount equal to the applicable number of Preferred
Investment Option Shares purchased. The Holder and the Company shall maintain records showing the number of Preferred Investment Option
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Preferred Investment Option, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Preferred Investment Option Shares hereunder,
the number of Preferred Investment Option Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$2.75</B>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment
Option may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall
be entitled to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
    and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
    in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
    either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of
    the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of
    the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
    hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of
    &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable
    Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
    pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Preferred Investment Option Shares that would be issuable upon exercise of this Preferred Investment Option in accordance
    with the terms of this Preferred Investment Option if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Purchasers
</FONT>of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
    of Preferred Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred Investment Option Shares purchased
    hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s
    balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
    if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
    of the Preferred Investment Option Shares to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred
    Investment Option Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144
    (assuming cashless exercise of the Preferred Investment Options), and otherwise by physical delivery of a certificate, registered
    in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Preferred Investment Option Shares
    to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
    date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading
    Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
    Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Preferred Investment Option Share Delivery
    Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the
    holder of record of the Preferred Investment Option Shares with respect to which this Preferred Investment Option has been exercised,
    irrespective of the date of delivery of the Preferred Investment Option Shares, provided that payment of the aggregate Exercise Price
    (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of
    Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any
    reason to deliver to the Holder the Preferred Investment Option Shares subject to a Notice of Exercise by the Preferred Investment
    Option Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
    of Preferred Investment Option Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
    Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Preferred Investment
    Option Share Delivery Date) for each Trading Day after such Preferred Investment Option Share Delivery Date until such Preferred
    Investment Option Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
    a participant in the FAST program so long as this Preferred Investment Option remains outstanding and exercisable. As used herein,
    &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the
    Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
    Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time)
    on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company
    agrees to deliver the Preferred Investment Option Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial
    Exercise Date and the Initial Exercise Date shall be the Preferred Investment Option Share Delivery Date for purposes hereunder,
    provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Preferred
    Investment Option Share Delivery Date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
    of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part, the
    Company shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery
    of the Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder
    to purchase the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred
    Investment Option shall in all other respects be identical with this Preferred Investment Option.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rescission
    Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares pursuant
    to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation
    for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other rights available
    to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option Shares
    in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option Share
    Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
    or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder
    of the Preferred Investment Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
    then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
    brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the
    number of Preferred Investment Option Shares that the Company was required to deliver to the Holder in connection with the exercise
    at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option
    of the Holder, either reinstate the portion of the Preferred Investment Option and equivalent number of Preferred Investment Option
    Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the
    number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations
    hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect
    to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
    under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide
    the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company,
    evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to
    it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
    to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Preferred Investment Option as required
    pursuant to the terms hereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
    Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
    this Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
    exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to
    such fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Charges,
    Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any issue or
    transfer tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which taxes
    and expenses shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder
    or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment
    Option Shares are to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for
    exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
    a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay
    all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or
    another established clearing corporation performing similar functions) required for same-day electronic delivery of the Preferred
    Investment Option Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing
    of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
    Preferred Investment Option, pursuant to the terms hereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder
shall not have the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment
Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Preferred Investment Option is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any
limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>,
that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make
any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company
(or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are
permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50%
or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares
of Common Stock or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred
Investment Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Preferred Investment Option from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder shall
only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility
equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying
price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period
beginning on the Trading Day immediately preceding the public announcement of the applicable Fundamental Transaction (or the consummation
of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&rsquo;s request pursuant to this Section
3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the
date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company
under this Preferred Investment Option and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Preferred Investment
Option a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred
Investment Option which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Preferred Investment Option (without
regard to any limitations on the exercise of this Preferred Investment Option) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Preferred Investment Option immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under
this Preferred Investment Option (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every
provision of this Preferred Investment Option and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer
instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor
Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity
or Successor Entities shall assume all of the obligations of the Company prior thereto under this Preferred Investment Option and the
other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The <FONT STYLE="background-color: white">Holder agrees to maintain any information
disclosed pursuant to this <U>Section 3(f)(ii)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Preferred Investment Option reduce the then current Exercise Price to any amount and for any period of time deemed appropriate
by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Preferred Investment Option and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Preferred Investment Option
at the principal office of the Company or its designated agent, together with a written assignment of this Preferred Investment Option
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Preferred Investment Option or Preferred Investment Options in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Preferred Investment
Option evidencing the portion of this Preferred Investment Option not so assigned, and this Preferred Investment Option shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Preferred
Investment Option to the Company unless the Holder has assigned this Preferred Investment Option in full, in which case, the Holder shall
surrender this Preferred Investment Option to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment
form to the Company assigning this Preferred Investment Option in full. The Preferred Investment Option, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Preferred Investment Option Shares without having a new Preferred Investment
Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment
Options upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Preferred Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained
by the Company for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof
from time to time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of
this Preferred Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an
effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may
be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, understands that the Preferred Investment Options are &ldquo;restricted
securities&rdquo; and have not been registered under the Securities Act of 1933, as amended, or any applicable state securities law,
and represents and warrants that it is acquiring this Preferred Investment Option and, upon any exercise hereof, will acquire the Preferred
Investment Option Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such
Preferred Investment Option Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities Act, and has no direct or indirect arrangement or understandings with any
other persons to distribute or regarding the distribution of such Preferred Investment Option. At the time the Holder was offered this
Preferred Investment Option, it was, and as of the date hereof it is, and on each date on which it exercises this Preferred Investment
Option, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act. The Holder, either alone
or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be
capable of evaluating the merits and risks of the prospective investment in the Preferred Investment Option, and has so evaluated the
merits and risks of such investment. The Holder is able to bear the economic risk of an investment in the Preferred Investment Option
and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock
certificate relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender
and cancellation of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred
Investment Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment
Option shall be determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred
Investment Option, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by
state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Preferred Investment Option or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Preferred Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered to the address of the Holder in the Warrant Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred
Investment Option to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether
such liability is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option
and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder
from time to time of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
<B>Microbot Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment
Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: _______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_______________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
_______________ __, ______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature: ___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: ____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 80px; width: 64px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            Financial Center</FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
    MA 02111</FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-542-6000</FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-542-2241
    fax</FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.mintz.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May
23, 2023

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25
Recreation Park Drive, Unit 108</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hingham,
MA 02043</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) of a Prospectus Supplement, dated May 22,
2023, to a Prospectus, dated December 4, 2020 (the &ldquo;<U>Prospectus and Prospectus Supplement</U>&rdquo;), filed pursuant to a Registration
Statement on Form S-3, Registration No. 333-250966 (the &ldquo;<U>Registration Statement</U>&rdquo;) and filed by the Company with the
Commission under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;). The Prospectus Supplement relates
to the sale of 655,569 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, $0.01 par value per share (the &ldquo;<U>Common
Stock</U>&rdquo;), pursuant to a Securities Purchase Agreement, dated May 22, 2023, between the Company and the purchasers named therein
(the &ldquo;<U>Purchase Agreement</U>&rdquo;). The Purchase Agreement will be filed as an exhibit to a Current Report on Form 8-K and
incorporated by reference into the Registration Statement. This opinion is being rendered in connection with the filing of the Prospectus
Supplement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given
to them in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion, we have (i) examined and relied upon: (A) the Registration Statement, the Prospectus and the Prospectus
Supplement, (B) the Company&rsquo;s Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect, and
(C) the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as
in our judgment are necessary or appropriate to enable us to render the opinion expressed below; and (ii) assumed that the Shares to
be sold by the Company will be sold at a price and on terms established by the Board of Directors of the Company or a duly constituted
pricing committee thereof in accordance with Section 153 of the Delaware General Corporation Law. As to certain factual matters, we have
relied upon a certificate of an officer of the Company and have not independently verified such matters. In rendering this opinion, we
have assumed the genuineness and authenticity of all signatures on signed documents; the authenticity of all documents submitted to us
as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of
certificates of public officials; and the due authorization, execution and delivery of all documents where due authorization, execution
and delivery are a prerequisite to the effectiveness thereof (except we have not made such assumption with respect to the Company).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any
other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws
of any state or any foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the
Registration Statement, the Prospectus and the Prospectus Supplement, will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item
601(b)(5) of Regulation S-K under the Securities Act and to the use of this Firm&rsquo;s name therein and in the Prospectus Supplement
under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit that we are in the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
                                            truly yours,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 22, 2023, between Microbot Medical Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its successors
and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<SUP>nd</SUP>)
Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial Center, Boston, MA
02111.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities
upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agent in connection with
the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a
majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or
to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $2.20 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full,
in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-250966 which registers the sale of the Shares
and Pre-Funded Warrants to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; color: blue"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double; letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Pre-Funded Warrants purchased hereunder
as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the
Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare Trust Company, with offices located at Meidinger Tower, 462 South 4th Street, Louisville, KY 40202,
and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $1,442,250 of Shares. Notwithstanding anything herein to the contrary, to the
extent that a Purchaser determines, in its sole discretion, that such Purchaser&rsquo;s Subscription Amount (together with such Purchaser&rsquo;s
Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would cause such
Purchaser&rsquo;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, or as such Purchaser
may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section
2.2(a). The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%)
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing
Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and Pre-Funded Warrants
as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable
at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely
by electronic transfer of the Closing documentation. Notwithstanding anything herein to the contrary, if at any time on or after the
time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to
the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to
be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall,
automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound
to purchase, such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement
Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided
further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser
as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any
such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any
such sale, if any. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus
Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo;
names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser;
upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment
therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 12:00 p.m. (New York City
time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver
the Pre-Funded Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall
be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited
basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
to the difference between (A) such Purchaser&rsquo;s Subscription Amount divided by the Per Pre-Funded Warrant Purchase Price and (B)
the number of Shares otherwise issuable to such Purchaser that would cause such Purchaser&rsquo;s Beneficial Ownership to be more than
the Beneficial Ownership Limitation with an exercise price equal to $0.0001 per share of Common Stock, subject to adjustment therein;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on
the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which
case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in
all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. Except as set forth in the SEC Reports, the Company hereby makes the following representations and
warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them
in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;)
and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required
pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to
each applicable Trading Market for the listing of the Shares and Pre-Funded Warrant Shares for trading thereon in the time and manner
required thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Pre-Funded Warrant Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock
the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Pre-Funded Warrants. The Company has prepared
and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on December 4,
2020, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.
The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the
Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for
that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by
the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement
and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form
S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities being
sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of
Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company as of the date set forth therein is as set forth in the SEC Reports. The Company has not issued any
capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock
options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of
the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result
of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital
stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale
of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other
than the Purchasers). Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any
Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance
of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities or instruments
of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of
any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Except as set forth in the SEC Reports, since the date of the latest audited
financial statements included within the SEC Reports, (i) there has been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise)
other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B)
liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with
the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares
of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or,
to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) except as set forth in the SEC
Reports, would have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any
current director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#9;<U>Environmental
Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. To the Company&rsquo;s knowledge, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC
Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the
date of this Agreement, except as would not be reasonably expected to have a Material Adverse Effect or as disclosed in the SEC Reports.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the
rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect or as disclosed in the
SEC Reports. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has been advised that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from,
providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or
such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 and in which the officer,
director or employee has a direct or indirect material interest other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules
and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except
as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Except as set forth in the SEC Reports, the Company and the Subsidiaries have established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls
and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The
Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Other than as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to terminate, or which to its knowledge is likely to have the effect of terminating, the registration of
the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is
current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus
Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company
and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct in all material respects
as of the date made and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges
and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#9;<U>Solvency</U>.
Except as disclosed in the SEC Reports, based on the consolidated financial condition of the Company as of the Closing Date, after giving
effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such
debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has
no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy
or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date set forth
therein all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary
has commitments For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or
amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties,
endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected
in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments
for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments
in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in
default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&#9;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all
foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis
for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#9;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#9;<U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company, such accounting firm
(i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial
statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#9;
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#9;<FONT STYLE="text-underline-style: double; letter-spacing: 0pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity. </U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">Anything
in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood
and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed,
to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities
issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any
Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing
of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities;
(iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or
indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have
any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further
understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that
the Securities are outstanding, including, without limitation, during the periods that the value of the Pre-Funded Warrant Shares deliverable
with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that
such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&#9;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of
the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&#9;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket
clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product
listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not
have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any
lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or
any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication
from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the
uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by
the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters
or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges
any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. <FONT STYLE="letter-spacing: -0.15pt">The properties, business and operations of the Company have
been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&#9;<U>Cybersecurity</U>.
(i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are
presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented
and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and
disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&#9;<FONT STYLE="letter-spacing: -0.15pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&#9;<FONT STYLE="letter-spacing: -0.15pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&#9;<FONT STYLE="letter-spacing: -0.15pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&#9;<FONT STYLE="letter-spacing: -0.15pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Pre-Funded Warrants, it will be either (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as
defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement
Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities
nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation
as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information
with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities
to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pre-Funded
Warrant Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
all or any portion of a Pre-Funded Warrant is exercised at a time when there is an effective registration statement to cover the issuance
or resale of the Pre-Funded Warrant Shares or if the Pre-Funded Warrant is exercised via cashless exercise, the Pre-Funded Warrant Shares
issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement
(or any subsequent registration statement registering the sale or resale of the Pre-Funded Warrant Shares) is not effective or is not
otherwise available for the sale or resale of the Pre-Funded Warrant Shares, the Company shall immediately notify the holders of the
Pre-Funded Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders
when the registration statement is effective again and available for the sale or resale of the Pre-Funded Warrant Shares (it being understood
and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Pre-Funded Warrant
Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement
(including the Registration Statement) registering the issuance or resale of the Pre-Funded Warrant Shares effective during the term
of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Pre-Funded Warrants have expired,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the
reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations
of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder
approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of
the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents in connection with
the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between
the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, on the one hand,
and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company
understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the
Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions
contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public
statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent
of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except
if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of
such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior
written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction
Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the
Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with
such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general corporate
purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of
trade payables in the ordinary course of the Company&rsquo;s business and prior practices); or (b) for the redemption of any Common Stock
or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members,
partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred, provided that the Indemnified Party executes an undertaking to reimburse amounts paid if indemnification is unavailable
hereunder. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party
against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Pre-Funded Warrant Shares pursuant to any exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Pre-Funded Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Pre-Funded Warrant Shares
on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market,
it will then include in such application all of the Shares and Pre-Funded Warrant Shares, and will take such other action as is necessary
to cause all of the Shares and Pre-Funded Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible.
The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market
and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading
Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company
or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until five (5) Trading Days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus Supplement and filing
a registration statement on Form S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the one year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price; <U>provided</U>, <U>however</U>, that, after six months following the Closing
Date, the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall
not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be
an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal
and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the
Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not
engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including,
without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Pre-Funded Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Pre-Funded Warrants. No additional legal opinion, other information or instructions shall
be required of the Purchasers to exercise their Pre-Funded Warrants. Without limiting the preceding sentences, no ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
form be required in order to exercise the Pre-Funded Warrants. The Company shall honor exercises of the Pre-Funded Warrants and shall
deliver Pre-Funded Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on
a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment
at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants
based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser
(or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon
each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the
Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file or by any other electronic means, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; or electronic signature
page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Pre-Funded Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any
such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for
such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Pre-Funded
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19&#9;<U>Saturdays,
Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">MBOT</FONT> SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Signature
of Authorized Signatory of Purchaser</I>:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: _______________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HINGHAM,
Mass., May 22, 2023 (GLOBE NEWSWIRE) &mdash; Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive
agreements for the purchase and sale of 655,569 shares of the Company&rsquo;s common stock at a purchase price of $2.20 per share of
common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur
on or about May 24, 2023, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company from the offering are expected to be $1,442,252, before deducting the placement agent&rsquo;s fees and
other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for the continued development,
commercialization and regulatory activities for the Company&rsquo;s LIBERTY<SUP>&reg;</SUP> Robotic System, expansion and development
of additional applications derived from the Company&rsquo;s existing IP portfolio, and for working capital and other general corporate
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares described above are being offered by the Company pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No.
333-250966) previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and declared effective by the SEC on
December 4, 2020. The offering of the securities is made only by means of a prospectus, including a prospectus supplement, forming a
part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will
be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available,
on the SEC&rsquo;s website at http://www.sec.gov or by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York,
NY 10022, by phone at (212) 865-5711 or e-mail at placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1D2228"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
the human body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The LIBERTY Robotic System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating
the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company
believes the LIBERTY Robotic System&rsquo;s remote operation has the potential to be the first system to democratize endovascular interventional
procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further information about Microbot Medical is available at <U>http://www.microbotmedical.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects&rdquo;
and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, the completion of the offering, the satisfaction of customary closing conditions related
to the offering, the intended use of proceeds from the offering, market conditions, risks inherent in the development and/or commercialization
of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company&rsquo;s core business focus program and cost reduction
plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it seeks additional working capital, any
failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory
approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical can be found under the heading &ldquo;Risk Factors&rdquo; in
Microbot Medical&rsquo;s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC&rsquo;s
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #1D2228"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #1D2228"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michal
Efraty<BR>
+972-(0)52-3044404<BR>
IR@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HINGHAM,
Mass., May 23, 2023 (GLOBE NEWSWIRE) &mdash; Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced
registered direct offering for the purchase and sale of 655,569 shares of the Company&rsquo;s common stock at a purchase price of $2.20
per share of common stock priced at-the-market under Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
gross proceeds to the Company from the offering were approximately $1,442,252, before deducting the placement agent&rsquo;s fees and
other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
continued development, commercialization and regulatory activities for the Company&rsquo;s LIBERTY<SUP>&reg;</SUP> Robotic System, expansion
and development of additional applications derived from the Company&rsquo;s existing IP portfolio, and for working capital and other
general corporate purposes<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares described above were offered by the Company pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-250966)
previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and declared effective by the SEC on December 4,
2020. The offering of the securities was made only by means of a prospectus, including a prospectus supplement, forming a part of the
effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the
SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC&rsquo;s website at http://www.sec.gov
or by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 865-5711 or e-mail
at placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Microbot
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
the human body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
LIBERTY Robotic System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes
the LIBERTY Robotic System&rsquo;s remote operation has the potential to be the first system to democratize endovascular interventional
procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Further
information about Microbot Medical is available at <U>http://www.microbotmedical.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects&rdquo;
and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, the intended use of proceeds from the offering, <FONT STYLE="background-color: white">market
conditions, risks inherent in the development and/or commercialization of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether
the Company&rsquo;s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on
its LIBERTY technology while it seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results
of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic,
need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot
Medical can be found under the heading &ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the Securities
and Exchange Commission (SEC), which are available on the SEC&rsquo;s web site at www.sec.gov. Microbot Medical disclaims any intent
or obligation to update these forward-looking statements, except as required by law</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Michal
Efraty</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">+972-(0)52-3044404</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">IR@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K %4# 2(  A$! Q$!_\0
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MC_\ 017%Q_\ )P,W_8NK_P"CZ[31?^0%I_\ U[1_^@BN+C_Y.!F_[%U?_1]
M'H)( R3@5Y?<%_BCXI-HF?\ A$-)G!G<' U"Y7^ >J+W]?RQTWQ)N)K3X<Z_
M-;R-%*EH^UT."..QKY(L_%WB+3;<6=CKFH6UM']R**X957Z &@#[?5%50JC"
:C@ # %%?$_\ PGGBW_H9=5_\"G_QHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mbot-20230522.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamOKbP9z5Z8qekhvWB2baka/yIsoqVURCWNltymwTcM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:MBOT="http://microbotmedical.com/20230522" elementFormDefault="qualified" targetNamespace="http://microbotmedical.com/20230522">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://microbotmedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20230522_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20230522_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mbot-20230522_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mbot-20230522_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/Cover" xlink:href="mbot-20230522.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139928185364304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 22,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MICROBOT
MEDICAL INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3078125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25
Recreation Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Unit 108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hingham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBOT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbot-20230522.xsd" xlink:type="simple"/>
    <context id="From2023-05-22to2023-05-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883975</identifier>
        </entity>
        <period>
            <startDate>2023-05-22</startDate>
            <endDate>2023-05-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-22to2023-05-22">0000883975</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-22to2023-05-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-22to2023-05-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-22to2023-05-22">2023-05-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-22to2023-05-22">MICROBOT MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-22to2023-05-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-22to2023-05-22">000-19871</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-22to2023-05-22">94-3078125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-22to2023-05-22">25 Recreation Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-05-22to2023-05-22">Unit 108</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-22to2023-05-22">Hingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-22to2023-05-22">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-22to2023-05-22">02043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-22to2023-05-22">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-22to2023-05-22">875-3605</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-22to2023-05-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-22to2023-05-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-22to2023-05-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-22to2023-05-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-22to2023-05-22">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-22to2023-05-22">MBOT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-22to2023-05-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-22to2023-05-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( *N MU:JQ"(6,P$  "("   /
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *N MU8D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *N MU9ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>mbot-20230522.xsd</File>
    <File>mbot-20230522_lab.xml</File>
    <File>mbot-20230522_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbot-20230522_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbot-20230522_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbot-20230522.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MBOT",
   "nsuri": "http://microbotmedical.com/20230522",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-05-22to2023-05-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://microbotmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-05-22to2023-05-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-23-018718-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-018718-xbrl.zip
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MM"T4XK5>$:XF66?$BT_ A*K:. _:1@@3[I0F !S!J+-?K9DF_>=^/D2*RR\
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MJ0DL58MH])9Z>8%O^9%;:^;)W.0<4C U,:$[8A?J1$#WI(00V!$==/-5O6H
MYIO1&I/-*@L=>T</QOL.K/\5W!,M0RO>\7?T#&(Q>8>_B5-C"_JF"4:C\[MI
M>D.,7MV.-;I^A#<%=R+2'=L1?Q^K+@QZ,PD&0RY4R#9K.;4%B@WSIA[VX#VO
MI#Z5"*=P8+:?/%4"E95N5^_J7>/H J77+Q79,1:Z))_"@B&&!6FONA\M<A!V
M@L#X#V1;L2%KS1QU2)>&-B2M//TE2>GFJ.D?W/$B^FC,VA9BH"_.E<"5+4(+
MFB<WET$#Y7FWSY$#LB+0?VL[9,$&<FOJM1'WEAYEN&K7-1[LAEB<]8P85K@\
M&L.N)ZN(D!T)5@-V&]Q%^+R:9VXWL73#7'!;F42I#@NM)8G@E:?R(!X=04!E
ME$B\QMT*M& <N-Z]X;ET.9L^$P:NNXY1WN(PZW;M42)\@2AYUTE%S,X<PO5!
M.JRX: M'B.4*2T WNO?T(;"&>CK&$F%"3X32&.AQ"Y9>(F+#LA^>GU)5>Z.=
M3@9Z:ZUVJEG11%;VC^$1P<IR4B@LI?P5')'^M[@=L:><8O&W)6>KTMXE9/$'
MZFPZ>6>U(YGAJ&/2"@MVJ.I)3P!5C5L+V W01(@WJ-%6MS.N3?9OBISR:/S3
M*/F8,@#<N+]SNU!U2,F18C8 -_#$8W@#?14/3"?2LT'0PXJ+;!*O02@H;%T>
M^\= IJ/Y)G!BMDAF+$' XK<RXT9A^';2?(VMP^+"L5L+.SR2GMA0?KJL;'5C
MW<GN)11B03<HQ=;Q=)RPX512L&OT6UMT_*+;O!N]QBO;)Y.X?V";C3"G;$*<
M'I62J+O%*Q(;&[_M6[D[-1PZ4+_"K71360!<AZ1[;U*[@3W7S?0\.CH\?HJV
MV@<NC,0FM30@7W**8'GX<Q*02OE8!X9U.:N" ;A^5&V\$]Y S4SG;M]V;\M
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M=]K%_G?9+B\3Z8!)--L=A]2&C?1R$M43M=88FHR66QQ#5EO#:N@)/A]15D0
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M*DNP2NR2RLKLG^/MCW>M:+OQ2++>'1&S*SF3;R^%NA__BD3[15H?1J^6MG\
M+187NBD&2 <E' ?:3B<SV:&ZG==T]S9C2\M_-BY$R<MYZX4]L,P^?@\YGT1]
M450G 2X4R(TSI'=\41R&*6DE=5"16"$YSB0M-%V1X0" D@H"JTS"GS;F.K)$
M,L,&Q=9/T]4;<>M-'A'20:X;/QQN#<KCF4ZLX&]YD7K^A27L^]UK%\TR2W[?
M:RLMC0&M^^H\'N6:4ER+G9_Y8$,+C""A1,=6,:B(+ /&=:O"@7%.)^?.=1EG
M;[@5)OQ#3TJP<\'<U(WDB"G%B*P/Y(L-[0.2R0:!KN%3=M [.SZ9=_NM\1NN
M\@082W.1]@'Q?;#.V7V<R),=:[%_:JLBJR\M?UD/T/-KT61<86&2*L]0<GLI
M(N[UKLX9$2>=!SQ&CG9V2/]1$L)\6F,>/ X[WN!-6]"7,$8.KP1UMLQ EO%2
M$20'+"=W_J$CZP(3JI*;?J$HV]0QOJB2A<V%'=#E)PVX,,DEJ7D&Q^)#>KT6
M?*MC?1MV2U#./L'*%.#A(?P<:>#L_=]AI".M'E(8X3"V$<'H1]__D_CP [A/
M#A_O=$!?$=6M/Y'32?]20='ABXTP8=PS5VYEZ9W+GS#.N]V$Q4\%7+(-H5+4
M\>FV'YX%E1J$HJ8;Z&0 !@.B*&T773..3*8!OW9P$QZL&VOO,4O.J7//*?EX
MD'V(5!>.]D.5T#WY"_<0(8/'P@XMT3;CMB@ZR;:0;RX6Y((7POE@DY;2/UC%
MDH7M03V*BL;X65DMZ@EU!M,5#3U5V<3JT?N#_&>?'Q[D)[OU]5%@*B*)>NF2
MG\_@[IS3,=WTR4KYB&.5D5P]_G<TQ)C-73 @J3E59)NR2&[5%7 $R(G(ML>^
M*17!:-;9_(#OT$2(QQI!TV*NYR>P&**_/_H_&I0RCN!-:H?:M3#=6/49PD8_
M,)\.Q2K9&NXZEG4(;K[H)T2:D!/A;F0-9Y/^JVJ!0A_.T\-0HH(L%<<_XW0(
M[P69*PS5RS=VG4T:M%>+1_!\*H<4-G90;^/Y^33?#6WR_$.R2G=B&,KXZV2^
M9KJL;&J_G]BZ24ZVT4L0TM!B;&/E7A"1[8Y[!,IU6[[3 I(EQQ7"#7R22?-U
M6&#0AA^$0\:>FU*&%6*98M#BS;4Q1:>M_!8JT;O<&,>4@=5BEUBW)"[SH 1U
M7ZZ?*(^A.=*#1*I1+W#S)WSNG'8$K/IE6]%7B;2!(,V^C:S?&0]U<VCU989Z
MAK;&!,Q-/O*$V6(!TH7NOK7Z41R-8X[HY@=[*#=W9$(-2LBOH2%0;C87)G[N
MIM%PST>22^ED:RO@M6#6@Z@C/4#.1@]JTV(+B6IWB*+;;?0N5/%%8,8)FMQ^
MDU3/=.(#.A891.@GLG1LW\XP@M)/\'+;0OUFL;<4DK&LQE] ]IGIT'?=ZB7A
ML)@T2P;M35^%O2>J#7SRI<E31HCGR0;+.Y@A93K)+*>6OT6S.KA;\N1Z@*-+
MWZ<,VNH$V01CK4X7?XWFR<O!S8+I[E5[I&)N9:=A\(U @'X8$A>D=S?1]XID
M-;!Q%+CFBWO+URR@0MI4#UW7#J/A^[(0"2=^$-KE<5]2P (0=:MDLL>,P^U/
MT!1*PBVSL;@P C>,TC"JUS:"SW-]=4TGWE(9FJ0UAAQ>E#IYW"Q0_470_LN
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M!( Y<Z'-2#:+-5TP&_!_!,#5,[EX?*O 5GH#1QY]1H^1C!N67!C?A;PG:#R
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M$&7 L.0$7/1)D,TF$3,J.-D<B4V+HA97[837%_'EC*DBL\C&ZXW)AF%EYBK
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MIHF^=B)'EO8/1V=O/@."X8?W@P\GO_X_4$L#!!0    ( *N MU9XL5B[+$L
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M0@O'B9^2;'"$;M4!"2+"AE0;HI\2(KV9)U)'8XPTJC;!6.**7.6%3/UX6^(
MRI- 9!Q(<CI5?$[?IFSS?B6G+$^E?;Y-I;W;5-KGVU3:>WDMMCE;VYRM6]4>
MKC99>4#-($H+51KU 4V__=G\T1$U;GH+&@,V80+)BA]+YEHLWS"["[ZJ0N[W
MK , 8@JR16L K8W^X 49O[4Z8Y)A*NGBG&CNM1NIZCG<BMI-3E$N!D:U(]O*
MN4AR@Z\427&:$^^3-!4W4\9T?0+5"Y-RAGGVF5T0QE.PPYUR$.%45WC1OJF1
M+DTS&44ZQ)(WY;_QIU&$C.-\XJ0AF08U?>DP72NR=F(DF'H&%%F,]?!49E9+
MN5HW?ZR61:12#B1BH)HC!H22.=5PC#:FK)QX'U\.KP.N 1'U6SBSQP/3Y3!@
M+A'R!CKD-BY$WE12AAW6:*X[7WI-N\P]F?Q6V0[.IV0;FJ,8P3:S@5#H,7HF
M'VO!:129TW(H^H+EB(5!BY6V,RY*^@0;2DV3.6X@9BN5-X>/<7?P6CGDNS!)
M(J:"@E0NH+F?MM<\A>)*KGJ0YHF8+,*7&#</46L,=101.JA0@&,#'EQ1+MED
M7J\E6#_P:LYUQ'EJW%"^E9ADZ,'P>M2J&9ID5&)<F=(E>4KMFQ%1K!JVYPHN
M!_RT94\IG(CL.)*!U"GZ0#F*JS<NLS3#K^QX?=0J#U=SI<0&B\(>LHF%B2U5
M EG$&"RFD/4,2P'+I?+[;I4LHS"?)XDE88AXGFVN:$%=Y\X)%I5TX=W@+296
M?%'PH<@('IF[[9CF311F1_D#S?<3EO6G)Y3F0A(KHXY<6M*Z@7$C^1""J"RC
MR;2,0B\)=,%&T4?P)1-()9[)P[>E9)KF8YRF<#7.GN;"?.)E0I;-T-#4]A2E
M9)T/5OL/*B\)DS. O*9JDFO$,6,/+IIY0XYIW*F$QK&V&'WU)D^;>!0V )N[
M9;N68^@T!%F.' 201Y\E@!-)<$;5\-GLCK>I0Q.=%$X;FV1%07T;W3:-O!S*
M C:Q"</2C?^"%(;(58SP2E$]F^GU@7U122]Q>C)1B")1U])Y S>:JIY%)O1-
M?K)-0^XCKGHTPJHXG#AGQXXP%P4[L7*J>AK^3!_\@PK0*<4;+M:XF6"=?3(+
M&UL%4BZGY@<+J+@!*VP%#[0BH@[23$$;P@LS#=&V_MH-]]=NPP9;,KP'4]]H
MN_]81,C;G&TLT%=$(P1V?S;*XRG;Z\=9,+:/%.:1 A^QG<Y1S-6?,W)?M#5B
M[:YF[O1?6%5=O%=H?X$>QT7LJIEVK"\Z93!^MRBC^1AC3^2Z5PI03S$@53)A
M0\-H[ZC)"(ZDTRW15S%(+> >OV;^C=UI>1[\N'Y0C"NG<J6*_PQJ A;7PW*T
MT$N!?J07%VW15O!M/L?9"KXM&=Z#J5]M=+C\ +CA!3PC94#JBU2G# 2Z2?S4
M4J/:MAI%2[J)"B-C:HUHJ(KIJ4'RV!F5Z;0M[;<NU1?C;D7SC=*BJ,,[3:_!
M<HV=J;8K^8 -HAPL#0)9XB:(E\P%L5H&7=6WO736V1\+XE(V%HX:Y[(N/^9'
M<OJS0%M/Y^V#O3=RJKCY]5<!G+#.,L>3[.,/+K/K"+@%_UL#P) ><F7J2]I5
MWW"Q"Y>2VZ4HF:5-4V]>7']UTN$U^I!-GB)GXOFJB=U+C$G@63AZP1XU6Z</
MO@4;'OU':G0IM2OH/YV! 6X:'/EEL-4>]KC18EAC59<NOQEEJ8[?\$<UZHY)
MY@>E;#:!_XW'\2B6*$P>Q9,AV.41.BWT%?"(WJ%U^7 3%@ ,(Q.!?U2"/83"
M9EQ,!"T(1_ HI#YNV2@J"NG>MJ#O/8$$P6?'4K*!RUI8FK^CST6E?.YPD&J8
MQ 7N]BB)%/7YTM6BN%WB5R$OF>#_&5B_WH)YDZZ99VD\6ERFN;PZ:ZOW;;[
MW>I]6S*\!U._VNP\R8,D*TQT%)CH?I9]+NJ8,Y17B*$O[N"'%G^!CFFIYA_B
M6XQ#@AD!!5OQ<P'[$(5JFI-F49B: 9:Z7OL+04Y8EEQ_ T?VCYS2^&*;TGBW
M*8TOMBF-]_):;#JV7L18@I60J-'+WUO@I$408<BOI70=?[A.JR$V9)6Q/^T'
MZ\GE3A;!W$_36#5&8^-8+Z^JK[D\;#79GHR!3YE=$KR7%>KPO3'\^2$[N0*A
M!="0*"]U,?C2YL4>\,U.F5U$9-$P+FI#_M$>6'8)AOX+V3P3K#Z)\@+SX=!Q
MS1 ,*D#<5W1+.U]UQQ-;L!E/S8[4[3!"D(S0=Q*R]LHRCX=<G'_"X*]N=E:O
M;SI2I1&:I'"^,-XU.> QM:DPA73[YHG@XS6(\^(RGCKDA^!<W8[T](;/)=EU
MCQ-%3,6[Z6@@F <F(8+W>&6R2W6.C58ZZ"3=CMT:^EG#)IB*.\P!B-J-?X.6
M71JM=@%H$6<E"A(\;V.L86C16]8/8-8R53B-]E/ES^NCQ99)[M0Q!;.:1<!H
M'Y0-D6:I+2Y=XR:O/"#J/",$C;JC<TSPBZ93,BA%=KHY>EE Z!=.&MC,F3#Z
MP[*4GRG]!9B[")S,0A?[22Q.KN""O!!SH;T='YA,LZ+G0P[9EP-&]S63AWDX
M7%,EV44V,]X5YS5$!.9L0DF767D3UMSGW6YG\ 51_'W^&.M^\]4,IKX/9:%I
MPZ;Y(AJ0G21-D1F&<="!QC::)4I:&[C][.BJZ$\]>89=%^2(8(Z7*@6%98]D
M&;OD\EDBA,)MQ 5$,,\FL^2"OE\ZB4!Q*=?+0<"N;AX*%^;M#@HD"CTOI%M-
MV0.!1-=9+TPN,^5?8L:=S8]NOS9];> [H%^CI80L!-9GX!9)S*,7DW;!S2$;
M8IYQ4MU>W@R<!J@*KDRU^:6-A!>GN".5,]9=:*1_C,?'R($>B==W52M"DX-(
M/&J'_/BRA0AL25^Q-Q;82 /)^T(4]V6U%.@Q(*3V]:_#Z]!(=2=MO?A\:?"\
M@C N1GGD)JQJ9[<^8> 4DG_,WN$&UVLU@U3 6FL* 4K?;W0"C3Q''X#<X&]P
M NZ<"66-P+XD"9<X,!!MUD9[Z=<\_ [<0IJY2:#PP2O4U><BBBB9G]3($6R/
M&LU-K,D[#F"Q3GT'IQ>ZIZ5,#@?KA)CR/*.@#E[""#@(\3*NG'!(PG21:2C$
M:&(TQ.F_CHLVJ74U[A^G9G(Z[=1J+0ZD&!D5#2I,WV)4<+ E,4!QC=]9I E1
M!N38-M$1@-YJ+F:WXW8(8LBQ>,1R-,7L$^X$)"S5Z.D'IGR@SYAJ K_$@;@^
M9[H'DXR 8?G3,R"E$7XUF\%!$4'[T4/NSW=0?;&2TNN_HTM.*E$?1%&C]",2
MYZTT1V=+@60_Z:PD/3I:93EM1PU+I D,44 I*SBMA,.GKPY^+F',5<RCS^.Z
M=&5AW"(9WF]4Q!55,!<\DJJ-T8)T&FY9M[/ Z*23=U4[/RE]D;;9MUG(+0SE
MNC+=3HLN8IUU3A50RNUQ2''D=7;EVFF[1NZ&;L>I_UG.9EW0/[.[SW=__?7/
M>E^:#EE?M"8:=5/MEQZ.EPEP:_:=U^!#KD&W0^_+/:VVQ)I0M1-!8D9< 2)_
M;V-C^U5U#5S7 Y'C:[/JFS%.5:+]NICIU]LZ$G:_=#LW/9+UFV-?1LF"X#UV
MA%NZ?1I2/T,%?T9'APKN?#?82YU#$P5OU;Z:6 FF5QH4>((0Y8/YY<GKLT\G
M;XKR]<_X9Q#ZX*2Z=*-P8!A]8F*J:UC45.7J(E=3I\$:+*HH<\S)($:+E3NX
M:\C1*$E#0C0V*50C"L);,1P9<FL,T)?S1;W&O9VD*IX\I\/V9[0C1HO6]#AB
MT],=X0SRI-XP2G?!V2.JNFX,0-2#IBB2^JJ#$)O9VC(,ECG!QCNL"7'6[FPJ
MFP+*0!JAZPNA0NF*%G&N"V5@NT$[ ,J^P-E5O([6=.*S<6'M75NJ^9B(V-AG
M0%T.BP(]!!8INSWLT\-P?=\@S/7+-LQUMV&N7[9AKGMY+;YZ4=]E*8@0S6*C
MVWG&\2M,1@!21[#K/5,P4-Q)UZP'='K?F205!RE99SN,J0 T9'?"V32)FQ&W
M^AZJ-(C_)&KE]'%4S9<4RIA2/P/.1.EV0AG>"R"2M,>'0NS!H^TCE.W.OXN
MD1A%$47;RM=Q<\?Y+T6DF?F;4VKNNBIUC6V<+M)Q=TCSD0[A5UD<:ITXS&;#
MLN]$<76T2NSK139,5,U'%HMD'3VZ)QU6BMF0-[1H8QN"3D81#TSMSFN& S;.
MIJXJHVPR!$VH<&(MA.N@R'>&^4&8#%NP$8[TTUMC\&*",)T-HU-[H_BJQ]&P
MB)H?@8::J*)@*%-Q/"ZQ<OR-'ZEIC"FY/-&J84_>",\G6=:*DW1$'9/CO3HF
MY55RV0HN6%24JS)S>K"T<HWL</20W QHQ<SRN=F6> R&,\)>+++A!(F%<0W(
M3O1\MNS[3S-R9:X],\\56+,<G4&MB[;VS9L;[DX:/^CU;))H7P))GTCR^$UT
M9"$2>_O1.-0*IB!;'R';ETYY'!5*6+# :A]0[,)J)DYM=:Q]6=]!#NY2CYU0
M@] WAFN<3+["*P@4P'@@5O)J._S5XZ94\[#.K.SO:6(U^'KA/>Q=99ZA6%>@
M%,-'_M7](:R?35_44!2%V; @TZ$41,[@(] "5@44"Z&P[/TH&C.&Z%90>(2!
M?!S=PO5+@\$-7^@;(8 ,*TJ2@IY>%-&GG%:>J%L@6W"@XEKE_%'/SZOKE-AA
M4%*=10"\6VDO#E]*;> 7.D&!J'H9*\=WG0Y@>C(6VM1 +[$,<CQAY).JE/NJ
M$9>QB))@'3M.6I3V;U0&ZU<X8N77]<KCD46JD6'#"GS,I<(=01]>*^G!7[&\
MGT+MP-C6$P([.L\#UY&'0G'=CNN^<04+^ZQ<WWU3HD@+)V&O2<X:/WTFL$(@
MBS0'Q_9ZH,FFAHL3.?<=5VH>Z!:0S2>6,51<*B=:^6Z_.4JP@%P7'8HI W/"
MDPT37CG;8&=5Q9ID I;-F0P+<614KL'-=(IZP_"2/@4K!-5,2R<A4W:4Z\"F
M/>5NISFZ7+V(5J>O%M_[4VN:ENWJ1:O=(:R\>JH-2$G9U<614:57UWP E:%Z
M3EGCTBD9I0HO,CN8A]&<Z%.3@>R#TU$+.361)AXN15/1 ),SDQ(]/A%.Q5GC
M5.S=ZW:<R[?5&#9@42/6&$Y >)ZB\#QT#796%@YG5$]HJ*A5=S/?D5"#SV02
M#M$\S*5A[>>([*2@YF"H.!78<P!"/$(.YFD.(O2<!RA4LI*E]CWSN)SE*=UN
M;8#ZJ=).J2WA;K1):*RNH- .CVKF3]_J,_C;J>##V>DILS^@#DTQ]C\>]VMV
M=M_I%0KV*.I/%](G#+/9N#C8^;$S%2D/=2 X>SX&I4LA%23*YC9F;AQR=1 >
M6;E--I*4OT4-4A>P=N*)]*H[62W&L,)U@2QSL?Z<[TEV#GRTIDT%RY2I;N>;
M:5/!"F4*M^1NM2FMS#0K4[73Z*.9^56ZTNI[O5Q5L@=,1F\CR:S4D(+;5)#<
MH;N=&^A'"Y+OOD8]ZG:J=ZBJ'<G4&O.1Q>A:0T5:,EH/!01?-B>1L?Z6IQ\%
M3>H1S]7 6-Q(6](']!7J4O"C:4O+H\M_W4:7[S:Z_-=M=/E>7HM-7U3(1L3;
M61JJ">.HG%O]40<G;R$@V>>&ZVX<B,%XDCEG,NE_D;Y#>;%H6W":+V=X.XIM
M(2YR=DY.(HJJ<=8Y<0KCNG<M%TJ0HK%(\7)K#_NVX[N)#.I\+'3)QJ [Y?/>
MPCE[TT''31_X NF^23Q"6"041!IDIV\@;/J<&3O7#BIC-!%\##OTQXRZA'K8
M$#>SY-HF@6)R#"J[:PK,DEQ2:ILVCU:+S0;L*;CKZ3L0S^A\1E^2;H XYGV.
M=*8\_V1'EU/4<Z_]?:8VNUIY#CUO->N(CF)850>[G2GJ@67)"@_ZIF$G96+.
ME&"XV. $CQLM-;+^,L<#C<H)+)A1PM4("[YLK-B9TXO'?Z88"]&ED)<;'*Q&
MQ>'YH/+X549IW%/01'/]LQ&_IB/GE7@IAF:;;PYG.CMDN.[-J5N?8'+D%RJ-
M_Z-T(@ \P]:T^5D]_FOJ%_%L9TF1Z2BJ/9;Z6=>"R'%A(U^$QZXK%>G&.F<<
M-I]KMU,]6 YM+]J^ZB5NLWO(86:3"5?N6&\ +U;?&]!V=7MO>ZV'LP)#^X4;
ML%OM@J@<2+]V'.Q,>$3.!,L(V5? [,,Z"WJZ!,R]D_@X5]; P[H4^QHU9=T&
MN_EI<=D4341>3TJ@J=S!]0AVR-O@NCF6"#/'X\'>"K+FV8HS@;?U< !JQEE3
M=SD*$W,B"TW7@>%:U,AN80,#ZX7P^RGXT/K2^)X. \NO\L@%^UNP1>P(HG>F
M]=J\U?X+O$%>MG-60^YMDU]#*>FK\R-X;B8AF*0-T6050RW+:SPU1M%)#@OZ
M1'[%:?C.6Y15P7Y-'7!5E (/RD D'ZY$'/<24/8Q2P+&<1YS"4]H@<ZPR89>
M<##D1U2!F_'<(@9HVW2L6^;82$OL4U@PPV]$''Z%'?,W[8/Q89AK61SU)",'
M%'&*$B/7B1@ZP477.1AOQH(3AN.AEC>R(MO78<'S]A[[P)PH?5B2U%.XEE]<
M)M:ZGQZF+_Z6AN7#/,7%L7">*9&H L9/TY5B"*D;-'VEJ2 6>-05^@#,H80Q
M*H=X>*@5P-I2VWQZP8"4";E$!Z3: BE=N\QH#086H*K@D4YB-#SV)0HG%OS-
MA9O9['4;ZN&-*[HVAX7T$9=Z[,+*G+6<Q^,L2;)K$\Y9,'?J'X(WT8A?&(@;
MBJ#?BZ5I"AI-SOH.7< K \&Y;$=\K1[M(LUX!^B'G"/.2>##G%3:K%>KLC,1
MH2[G<0U-F"E++M35<%&DSDGEY+/'6!=4<+2B+WJ"Z&;.C5_(KL2%C2I>SNJ
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M=I9M"MRQ]4W\<J%TRH8M$*,+":^[48#WO;V]5O>@<_CFS39\2LRD*DT"9,"
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M#VP(*:88'2OO,\5X   A"UTFD6&9('.SE02957(0<2PP*&MYT9_1=.4TW7:
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M &+8M.-1B@*$H^FL#PVA]@G&59)%.%5>KL2VK*-Y%JUK0$"[)B0M85"@0.Y
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MDID  #V: P *              "  0    !E>#$P+3$N:'1M4$L! A0#%
M  @ JX"W5GBQ6+LL2P  #O(!  D              ( !NID  &5X-"TQ+FAT
M;5!+ 0(4 Q0    ( *N MU:@KQ\OI@D  )PQ   )              "  0WE
M  !E>#4M,2YH=&U02P$"% ,4    " "K@+=64?PH(WP,  !2,@  "@
M        @ ':[@  97@Y.2TQ+FAT;5!+ 0(4 Q0    ( *N MU8^?7\T/0P
M )8T   *              "  7[[  !E>#DY+3(N:'1M4$L! A0#%     @
MJX"W5HXVAFYT&0  _\X   L              ( !XP<! &9O<FTX+6LN:'1M
M4$L! A0#%     @ JX"W5A;W*#!3 P  S@P  !$              ( !@"$!
M &UB;W0M,C R,S U,C(N>'-D4$L! A0#%     @ JX"W5@RN\&S^"@  @(8
M !4              ( ! B4! &UB;W0M,C R,S U,C)?;&%B+GAM;%!+ 0(4
M Q0    ( *N MU8V)XR+7 <  .-7   5              "  3,P 0!M8F]T
G+3(P,C,P-3(R7W!R92YX;6Q02P4&      D "0 4 @  PC<!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
